March 15, 2014
Sinovac Biotech, Ltd. (NASDAQ: SVA) lowered its full year revenue guidance from $60-67m to $40-45m, which was somewhat expected (notes 09/30 and 10/22) but should result in SVA share weakness nonetheless, Piper Jaffray reports. “We...(read more)
Sinovac Biotech, Ltd. (NASDAQ: SVA) appoints new CFO Jacob Ho, whose experience and credibility should help fair well for investor confidence. In a research report PiperJaffray writes, "We spoke to SVA's newly hired CFO, Jacob Ho,...(read more)
(Shocked Investor, 11/9/09)
We track the companies that make H1N1-related products on this site. The top performer year-to-date is BCRX (Biocryst), with a staggering return of 723%, followed by SVA (Sinovac), +492%....(read more)
Sinovac Biotech (SVA) Company Overview
There is no analysis for SVA yet. But you can go to Wikinvest to help create one!